FI964792A0 - Modulering av raf-genexpression med antisense-oligonukleotider - Google Patents
Modulering av raf-genexpression med antisense-oligonukleotiderInfo
- Publication number
- FI964792A0 FI964792A0 FI964792A FI964792A FI964792A0 FI 964792 A0 FI964792 A0 FI 964792A0 FI 964792 A FI964792 A FI 964792A FI 964792 A FI964792 A FI 964792A FI 964792 A0 FI964792 A0 FI 964792A0
- Authority
- FI
- Finland
- Prior art keywords
- oligonucleotides
- raf
- altering
- gene expression
- antisense oligonucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/250,856 US5563255A (en) | 1994-05-31 | 1994-05-31 | Antisense oligonucleotide modulation of raf gene expression |
PCT/US1995/007111 WO1995032987A1 (en) | 1994-05-31 | 1995-05-31 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF raf GENE EXPRESSION |
Publications (2)
Publication Number | Publication Date |
---|---|
FI964792A0 true FI964792A0 (sv) | 1996-11-29 |
FI964792A FI964792A (sv) | 1996-11-29 |
Family
ID=22949424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI964792A FI964792A (sv) | 1994-05-31 | 1996-11-29 | Modulering av raf-genexpression med antisense-oligonukleotider |
Country Status (12)
Country | Link |
---|---|
US (4) | US5563255A (sv) |
EP (1) | EP0763052B1 (sv) |
JP (2) | JP3231779B2 (sv) |
AT (1) | ATE280772T1 (sv) |
AU (1) | AU689267B2 (sv) |
CA (1) | CA2191795C (sv) |
DE (1) | DE69533697T2 (sv) |
FI (1) | FI964792A (sv) |
HU (1) | HUT76675A (sv) |
IL (1) | IL113804A (sv) |
NO (1) | NO965080D0 (sv) |
WO (1) | WO1995032987A1 (sv) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465188B1 (en) * | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Nucleic acid ligand complexes |
US5981731A (en) * | 1994-05-31 | 1999-11-09 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of B-raf gene expression |
US5744362A (en) * | 1994-05-31 | 1998-04-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
KR100211178B1 (ko) * | 1994-05-31 | 1999-07-15 | 파샬 비. 린네 | 라프유전자 발현의 안티센스 올리고뉴클레오티드 조절 |
US6410518B1 (en) * | 1994-05-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US6358932B1 (en) * | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US6090626A (en) * | 1994-05-31 | 2000-07-18 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of raf gene expression |
US6608035B1 (en) * | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US8071737B2 (en) * | 1995-05-04 | 2011-12-06 | Glead Sciences, Inc. | Nucleic acid ligand complexes |
US6699843B2 (en) * | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
US6229002B1 (en) * | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
HUP9802445A3 (en) * | 1995-08-01 | 1999-03-29 | Novartis Ag | Liposomal oligonucleotide compositions and process for inhibiting the human raf |
GB9519109D0 (en) * | 1995-09-19 | 1995-11-22 | Ciba Geigy Ag | Compositions |
GB9604669D0 (en) * | 1996-03-05 | 1996-05-01 | Ciba Geigy Ag | Chemical compounds |
US5744460A (en) * | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
AU727939B2 (en) * | 1996-04-03 | 2001-01-04 | Merck & Co., Inc. | A method of treating cancer |
US6027892A (en) * | 1996-12-30 | 2000-02-22 | Chang Esther H | Compositions and methods for reducing radiation and drug resistance in cells |
US6803360B1 (en) | 1996-12-30 | 2004-10-12 | Georgetown University | Compositions and methods for reducing radiation and drug resistance in cells |
US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
AU6578298A (en) | 1997-03-21 | 1998-10-20 | President And Fellows Of Harvard College | Antisense inhibition of angiogenin expression |
US6126965A (en) * | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
US7262173B2 (en) * | 1997-03-21 | 2007-08-28 | Georgetown University | Chemosensitizing with liposomes containing oligonucleotides |
US20030036516A1 (en) * | 1997-09-10 | 2003-02-20 | Sudhir Agrawal | Method for using oligonucleotides having modified cpg dinucleotides |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6492111B1 (en) * | 1998-11-25 | 2002-12-10 | Isis Pharmaceuticals, Inc. | In situ binary synthesis of biologically effective molecules |
US6114517A (en) * | 1998-12-10 | 2000-09-05 | Isis Pharmaceuticals Inc. | Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules |
US6365351B1 (en) * | 1999-01-29 | 2002-04-02 | Avi Biopharma, Inc. | Non-invasive method for detecting target RNA |
CA2850318A1 (en) | 1999-02-26 | 2000-08-31 | The University Of British Columbia | Trpm-2 antisense therapy |
FR2790955B1 (fr) * | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
US6147200A (en) * | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US6677445B1 (en) | 1999-08-27 | 2004-01-13 | Chiron Corporation | Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
DE10020138A1 (de) * | 2000-04-14 | 2001-10-31 | Ulf R Rapp | Nukleinsäure codierend für zumindest eine raf Teilsequenz mit einer MEKK1 Bindungsstelle |
DK1295611T3 (da) * | 2000-06-20 | 2010-10-04 | Dainippon Sumitomo Pharma Co | Oligonukleotid-transformerende forbindelser |
US6867349B2 (en) * | 2000-07-31 | 2005-03-15 | Regents Of The University Of Minnesota | Inhibition of gene expression using polynucleotide analogues |
US20070021360A1 (en) * | 2001-04-24 | 2007-01-25 | Nyce Jonathan W | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase |
ES2324525T3 (es) * | 2001-06-20 | 2009-08-10 | Dainippon Sumitomo Pharma Co., Ltd. | Metodo para promover transferencia de acidos nucleicos. |
CA2487809A1 (en) * | 2002-06-18 | 2003-12-24 | Archemix Corp. | Aptamer-toxin molecules and methods for using same |
US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
CA2942791C (en) * | 2002-11-25 | 2019-08-20 | Masafumi Matsuo | Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
CA2526636C (en) * | 2003-05-20 | 2012-10-02 | Bayer Pharmaceuticals Corporation | Diaryl ureas for diseases mediated by pdgfr |
EP1696034A4 (en) * | 2003-12-19 | 2006-12-27 | Dainippon Sumitomo Pharma Co | NUCLEIC ACID TRANSFER METHOD |
WO2005094899A1 (en) * | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
US8101350B1 (en) * | 2004-05-24 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Modulation of exportin 5 expression |
US20090062184A1 (en) * | 2005-03-24 | 2009-03-05 | Dainippon Sumitomo Pharma Co., Ltd. | Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
WO2007014150A2 (en) * | 2005-07-22 | 2007-02-01 | Neopharm, Inc. | Method of administering liposomes containing oligonucleotides |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
PL2010528T3 (pl) | 2006-04-19 | 2018-03-30 | Novartis Ag | 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
SI2805945T1 (sl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP) |
EP2132177B1 (en) | 2007-03-01 | 2013-07-17 | Novartis AG | Pim kinase inhibitors and methods of their use |
KR20100017866A (ko) | 2007-05-21 | 2010-02-16 | 노파르티스 아게 | Csf-1r 억제제, 조성물 및 사용 방법 |
CA2690191C (en) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
JP6073677B2 (ja) | 2009-06-12 | 2017-02-01 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 縮合複素環式化合物およびそれらの使用 |
CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
WO2011097407A1 (en) | 2010-02-04 | 2011-08-11 | Ico Therapeutics Inc. | Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
JP2013522292A (ja) | 2010-03-16 | 2013-06-13 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | インダゾール化合物およびそれらの使用 |
US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
US8518907B2 (en) | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
WO2012143879A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
AU2013323508B2 (en) | 2012-09-28 | 2017-11-02 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
ES2651347T3 (es) | 2012-11-28 | 2018-01-25 | Merck Sharp & Dohme Corp. | Composiciones y métodos para el tratamiento del cáncer |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
EP3525785A4 (en) | 2016-10-12 | 2020-03-25 | Merck Sharp & Dohme Corp. | KDM5 INHIBITORS |
CN118267470A (zh) | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
WO2024180169A1 (en) | 2023-03-02 | 2024-09-06 | Carcimun Biotech Gmbh | Means and methods for diagnosing cancer and/or an acute inflammatory disease |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190931A (en) * | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4871838A (en) * | 1985-07-23 | 1989-10-03 | The Board Of Rijks Universiteit Leiden | Probes and methods for detecting activated ras oncogenes |
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5194428A (en) * | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
US5276019A (en) * | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5264423A (en) * | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5004810A (en) * | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
US5135917A (en) * | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
US5541307A (en) * | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
WO1994008003A1 (en) * | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
AU2552492A (en) * | 1991-08-23 | 1993-03-16 | United States of America as represented by The Secretary Department of Health and Human Services, The | Raf protein kinase therapeutics |
JPH08506000A (ja) * | 1991-09-16 | 1996-07-02 | アメリカ合衆国 | C−raf−1遺伝子検出方法 |
AU6080294A (en) * | 1992-12-31 | 1994-08-15 | Texas Biotechnology Corporation | Antisense molecules directed against genes of the (raf) oncogene family |
WO1994023755A1 (en) * | 1993-04-09 | 1994-10-27 | Board Of Regents Of The University Of Nebraska | Novel methods and compositions for the treatment of ras-activated cancer with heterotypic anti-raf antisense oligonucleotides |
CA2206915A1 (en) * | 1994-12-21 | 1996-06-27 | Konstantinos Skobridis | Oligonucleotide-dendrimer conjugates |
-
1994
- 1994-05-31 US US08/250,856 patent/US5563255A/en not_active Expired - Lifetime
-
1995
- 1995-05-21 IL IL11380495A patent/IL113804A/xx not_active IP Right Cessation
- 1995-05-31 JP JP50125796A patent/JP3231779B2/ja not_active Expired - Lifetime
- 1995-05-31 DE DE69533697T patent/DE69533697T2/de not_active Expired - Lifetime
- 1995-05-31 CA CA002191795A patent/CA2191795C/en not_active Expired - Lifetime
- 1995-05-31 WO PCT/US1995/007111 patent/WO1995032987A1/en active IP Right Grant
- 1995-05-31 EP EP95922217A patent/EP0763052B1/en not_active Expired - Lifetime
- 1995-05-31 AU AU26982/95A patent/AU689267B2/en not_active Expired - Fee Related
- 1995-05-31 AT AT95922217T patent/ATE280772T1/de not_active IP Right Cessation
- 1995-05-31 HU HU9603277A patent/HUT76675A/hu unknown
-
1996
- 1996-11-28 NO NO965080A patent/NO965080D0/no not_active Application Discontinuation
- 1996-11-29 FI FI964792A patent/FI964792A/sv unknown
-
2000
- 2000-01-18 JP JP2000008654A patent/JP3121599B2/ja not_active Expired - Fee Related
-
2011
- 2011-07-18 US US13/185,406 patent/US20120149755A1/en not_active Abandoned
-
2012
- 2012-11-15 US US13/678,432 patent/US20130079387A1/en not_active Abandoned
-
2013
- 2013-07-31 US US13/956,213 patent/US20140187601A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE280772T1 (de) | 2004-11-15 |
JP2000152797A (ja) | 2000-06-06 |
HU9603277D0 (en) | 1997-01-28 |
JP3231779B2 (ja) | 2001-11-26 |
DE69533697T2 (de) | 2006-02-09 |
JPH09507502A (ja) | 1997-07-29 |
HUT76675A (en) | 1997-10-28 |
FI964792A (sv) | 1996-11-29 |
JP3121599B2 (ja) | 2001-01-09 |
AU689267B2 (en) | 1998-03-26 |
IL113804A (en) | 2000-12-06 |
WO1995032987A1 (en) | 1995-12-07 |
US20140187601A1 (en) | 2014-07-03 |
CA2191795A1 (en) | 1995-12-07 |
CA2191795C (en) | 2003-06-10 |
EP0763052B1 (en) | 2004-10-27 |
US20120149755A1 (en) | 2012-06-14 |
US5563255A (en) | 1996-10-08 |
EP0763052A4 (en) | 1998-10-14 |
US20130079387A1 (en) | 2013-03-28 |
NO965080L (no) | 1996-11-28 |
NO965080D0 (no) | 1996-11-28 |
IL113804A0 (en) | 1995-08-31 |
EP0763052A1 (en) | 1997-03-19 |
DE69533697D1 (de) | 2004-12-02 |
AU2698295A (en) | 1995-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI964792A (sv) | Modulering av raf-genexpression med antisense-oligonukleotider | |
ATE216705T1 (de) | Antisense-oligonukleotidmodulation der raf- genexpression | |
DE69403642D1 (de) | 7-deazapurin modifizierte oligonukleotide | |
CY1110633T1 (el) | Τροποποιηση αντιθετης φορας της εκφρασης σουρβιβινης | |
DE60143901D1 (de) | Antisense-modulation der clusterinexpression | |
EP1507005A3 (en) | Antisense modulation of BCL-X expression | |
EP1123414A4 (en) | ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4 | |
EP1135402A4 (en) | ANTISENSE MODULATION OF THE EGR-1 EXPRESSION | |
EP1189918A4 (en) | ANTISENSE MODULATION OF INTEGRIN BETA 3 EXPRESSION | |
ATE465261T1 (de) | Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken | |
WO2003105755A3 (en) | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION | |
FI961202A0 (sv) | Grb3-3-gen, dess varianter och deras användningar | |
EP1248633A4 (en) | ANTISENSE MODULATION OF GLYCOGENE SYNTHASE KINASE 3 BETA EXPRESSION | |
EP1235924A4 (en) | ANTISENSE MODULATION OF KAPPA B NUCLEAR FACTOR RECEPTOR ACTIVATOR (RANK) EXPRESSION | |
WO2002046367A3 (en) | Antisense modulation of cellular apoptosis susceptibility gene expression | |
EP1173458A4 (en) | ANTISENSE MODULATION OF SRA EXPRESSION | |
EP1248635A4 (en) | ANTISENSE MODULATION OF THE GLYCOGEN SYNTHASE-KINASE-3ALPHA EXPRESSION | |
EP1210454A4 (en) | ANTISENSE MODULATION OF SHP-1 EXPRESSION | |
BR0016347A (pt) | Oligonucleotìdios antisenso |